Shuttle Pharmaceuticals Holdings, Inc.
SHPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SHPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SHPH
Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer, currently facing significant liquidity challenges after winding down clinical trials and acquiring Molecule.ai.
Key risk: Liquidity and going concern
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Tracking 1 clinical trial for Shuttle Pharmaceuticals Holdings, Inc..
Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer, currently facing significant liquidity challenges after winding down clinical trials and acquiring Molecule.ai.
- Cash & equivalents of $1.1M as of 2026-03-31 [sec].
- Net income of -$2.2M as of 2026-03-31 [sec].
- Shareholders' equity of $2.3M as of 2026-03-31 [sec].
- Working capital deficit of approximately $7.5M as of December 31, 2025 [sec_mda · as of 2026-03-31].
- Acquired Molecule.ai for $3.0M in cash, contributing to increased liabilities and cash burn [sec_mda · as of 2026-03-31].
What works
- The company has intangible assets, net of $9.8M as of December 31, 2025, reflecting the Molecule.ai acquisition [sec · filed 2026-02-17].
- Management is actively evaluating strategic options and alternatives to address financial position [sec_mda · as of 2025-11-13].
What to weigh
- The company has a working capital deficit of approximately $7.5M as of December 31, 2025, indicating severe liquidity constraints [sec_mda · as of 2026-03-31].
- The company has incurred losses since inception and does not expect to generate positive cash flows from operations in the near future [sec_mda · as of 2026-03-31].
- The primary CRO, Theradex Systems, terminated the master agreement and demanded immediate payment of outstanding amounts, disrupting clinical trial operations [sec_mda · as of 2026-03-31].
- Current liabilities increased 419% year-over-year as of December 31, 2025, driven by contingent consideration and consideration payable from the Molecule.ai acquisition [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
Cash paid for Molecule.ai acquisition and clinical trial wind-down costs
“cash paid for the Molecule.ai asset acquisition of $3.0 million, costs incurred in winding down the Company's clinical trials”
SEC filings · February 17, 2026
No expectation of positive cash flows from operations
“We do not expect to generate positive cash flows from operating activities in the near future.”
SEC MD&A · March 31, 2026
Risks & what to watch (4)›
Key risks
- Liquidity and going concern — Working capital deficit of $7.5M as of Dec 31, 2025; cash only $1.1M as of Mar 31, 2026 [sec_mda · as of 2026-03-31].
- CRO termination disrupts trials — Theradex terminated master agreement and demanded payment, halting clinical trial support [sec_mda · as of 2026-03-31].
- No revenue and ongoing losses — Company has incurred losses since inception, net loss $2.2M in latest quarter [sec].
- Debt and contingent liabilities — Current liabilities include $2.0M contingent consideration and $4.4M consideration payable from Molecule.ai acquisition [sec_mda · as of 2026-03-31].
What to watch
- Ability to raise additional financing to fund operations and address working capital deficit [sec_mda · as of 2026-03-31].
- Outcome of strategic alternatives evaluation and potential business impacts [sec_mda · as of 2025-11-13].
- Resolution of the CRO termination and its effect on clinical development plans [sec_mda · as of 2026-03-31].
- Progress of Molecule.ai integration and any value realization from intangible assets [sec · filed 2026-02-17].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Shuttle Pharmaceuticals Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Shuttle Pharmaceuticals Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
1.9 months
D/E 2.53 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
6 buys · 5 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$46K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 46,217 | $31K |
| boothbay fund management, llc | 20,360 | $14K |
| kelleher financial advisors | 600 | $407 |
| morgan stanley | 27 | $18 |
Short Interest
as of Apr 30, 2026- % of float
- 1.3%
- Days to cover
- 0.3
- Shares short
- 71,193
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SHPH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Shuttle Pharmaceuticals Holdings, Inc.?
Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer, currently facing significant liquidity challenges after winding down clinical trials and acquiring Molecule.ai.
Who is the CEO of Shuttle Pharmaceuticals Holdings, Inc.?
Mr. Christopher Robert Cooper BBA, M.B.A. is the chief executive officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH).
Where is Shuttle Pharmaceuticals Holdings, Inc. headquartered?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is headquartered in Gaithersburg, MD, United States.
What therapeutic areas does Shuttle Pharmaceuticals Holdings, Inc. focus on?
Shuttle Pharmaceuticals Holdings, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.